Neisseria meningitidis serogroup B Glycoconjugates
US6638513B2 · kind B2 · utility
10Cited by
13References
12Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Aug 7, 1997 |
| Grant date | Oct 28, 2003 |
| Priority date | — |
| Expiry date | Aug 7, 2017 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY10S977/917
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention pertains generally to Neisseria meningitidis serogroup B glycoconjugates. More particularly, the invention pertains to glycoconjugates formed from a Neisseria meningitidis serogroup B capsular oligosaccharide derivative (MenB OS derivative) in which sialic acid residue N-acetyl groups are replaced with N-acyl groups. The invention also pertains to vaccine formulations containing the glycoconjugates, methods of making the vaccine formulations, and methods of using the vaccine formulations to treat or prevent Neisseria meningitidis serogroup B or E. coli K1 disease in a mammalian subject.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.